JD Health schedules 29 June 2026 AGM; seeks director re-elections, Deloitte re-appointment and renewal of share mandates

Bulletin Express
06/05

JD Health International Inc. will convene its 2026 annual general meeting at 10:00 a.m. on Monday, 29 June 2026, at Building A, No. 18 Kechuang 11 Street, Yizhuang Economic and Technological Development Zone, Beijing.

Key resolutions to be tabled:

• 2025 Financials: Shareholders will vote to receive and adopt the audited consolidated results and accompanying reports for the year ended 31 December 2025.

• Board Composition: – Executive Director: Dong Cao is nominated for re-election. – Non-executive Director: Company founder Richard Qiangdong Liu is nominated for re-election. – Independent Non-executive Director: Ling Li is nominated for re-election.

• Director and Auditor Remuneration: The board seeks authority to set director compensation and to determine fees for the external auditor.

• Auditor Re-appointment: Deloitte Touche Tohmatsu is proposed to continue as auditor until the next AGM.

• General Mandates: – Issuance Mandate: Authority to allot, issue or deal with shares up to 20% of the company’s issued share capital, excluding treasury shares and repurchased shares pending cancellation, during the mandate period. – Repurchase Mandate: Authority to repurchase up to 10% of issued shares on the Stock Exchange of Hong Kong or other recognised bourses. – Extension Mandate: The issuance limit may be increased by the number of shares repurchased under the buy-back mandate, capped at an additional 10% of issued share capital.

Voting method: All resolutions will be decided by poll in accordance with Hong Kong Listing Rules.

Key timetable details:

• Share transfer books and register closure: 24 June 2026–29 June 2026 (both days inclusive). Transfers must be lodged by 4:30 p.m. on 23 June 2026 to qualify for AGM attendance and voting rights. • Proxy submission deadline: 10:00 a.m. on Saturday, 27 June 2026.

As of the notice date (5 June 2026), the board comprises one executive director, one non-executive director and five independent non-executive directors.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10